Nanotek Remedies Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 29-06-2024
- Paid Up Capital ₹ 0.50 M
as on 29-06-2024
- Company Age 18 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 7.75 M
as on 29-06-2024
- Revenue -36.01%
(FY 2021)
- Profit -3617.63%
(FY 2021)
- Ebitda -128.05%
(FY 2021)
- Net Worth -50.85%
(FY 2021)
- Total Assets -34.25%
(FY 2021)
About Nanotek Remedies
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹7.75 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ratan Singh, Shyama Singh, Santosh Agarwal, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231MH2006PTC160936
- Company No.
160936
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Apr 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nanotek Remedies?
Board Members(4)
Financial Performance and Corporate Structure Insights of Nanotek Remedies.
Nanotek Remedies Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 36.01% decrease. The company also saw a substantial fall in profitability, with a 3617.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 50.85%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nanotek Remedies?
In 2021, Nanotek Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charakdhar Diagnostics Private Limited
Active
26 years 10 months Ratan Singh and Shyama Singh are mutual person
Adarsh Satendra Cold Storage And Allied Industries Limited
Active 25 years 6 months Ratan Singh and Shyama Singh are mutual person
M G M Fitness Centre Private Limited
Active 26 years 9 months Ratan Singh and Shyama Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Siemens Financial Services Private Limited Creation Date: 05 Aug 2014 | ₹3.35 M | Satisfied |
Allahabad Bank Creation Date: 22 Feb 2012 | ₹2.00 M | Satisfied |
Allahabad Bank Creation Date: 23 Sep 2009 | ₹2.40 M | Satisfied |
How Many Employees Work at Nanotek Remedies?
Unlock and access historical data on people associated with Nanotek Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nanotek Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nanotek Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
